Search

Your search keyword '"Pieters, M. S. M."' showing total 14 results
Start Over Author "Pieters, M. S. M."
14 results on '"Pieters, M. S. M."'

5. Abstracts of papers Clinical Pharmacological meeting

Author

van Meyel, J. J. M., Smits, P., Gribnau, F. W. J., Van Bortel, L. H. A. B., van Herode, T., Smeets, F. A. H., Reneman, R. S., Struyker Boudler, H. A. J., Aengevaeren, W., Corstens, F., v. d. Werf, T., Thien, Th., Buijsrogge, J -P. H. C., Thien, Th, Hooymans, P. M., Pouwels, M. J., v. d. Aa, G. C. H. M., Pouwbls, M. J., Diepstraten, J. M. W. J., Koopmans, P. P., van der Aa, G. C. H. M., Leeuwenkamp, O. R., Van Per Wiel, H. E., van der Vijgh, W. J. F., Greuter, H., Barto, R., Netelenbos, J. C., Lips, P., de Vos, D., Siee, P. H. Th. J., Stevenson, D., de Vos, P., Slee, P. H. Th. J., Ooslerhuis, B., Nehmiz, G., Cornelissen, P. J. G., Zuiderwijk, P. B. M., Jeuring, H. J., Jonkman, J. H. G., Su, C. A. P. F., van Tol, R. G. L., van Riel, A., Kerremans, A. L. H., van Kalken, C. K., de Jong, J., van der Hoeven, J. J. M., van der Vijgh, W. J. F., Pinedo, H. M., Kroon, C., de Boer, A., van der Meer, F. J. M., Edelbroek, P. M., Schoemaker, H. C., Cohen, A. F., van Steveninck, A. L., Kroon, J. M., Pieters, M. S. M., Breimer, D. D., Tukker, J. J., and Mculendijk, A. J. M.

Published
1989
Full Text
View/download PDF

7. Neurotoxiclty Scale

Author

Aldenkamp, A. P., primary, Baker, G. A., additional, Pieters, M. S. M., additional, Schoemaker, H. C., additional, Cohen, A. F., additional, and Schwabe, S., additional

Published
1995
Full Text
View/download PDF

11. Pharmacodynamics and Pharmacokinetics of a Single Oral Dose of Nitrazepam in Healthy Volunteers: An Interethnic Comparative Study between Japanese and European Volunteers

Author

Gerven, J. M. A., Uchida, E., Uchida, N., Pieters, M. S. M., Meinders, A. J., Schoemaker, R. C., Nanhekhan, L. V., Kroon, J. M., Visser, S. J., Altorf, B., Yasuda, K., Yasuhara, H., and Cohen, A. F.

Abstract

Potential interethnic differences in drug disposition and effects between Japanese and white subjects hamper the registration in Japan of medications already used in Western countries. This double‐blind, placebo‐controlled, crossover study was conducted to compare the pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam (5 mg) in age‐ and sex‐matched Japanese (n = 8) and white (n = 8) healthy volunteers. The study was performed in centers in Japan and the Netherlands using the same methods and study design. Subjects were individually matched for gender, age, and body stature. Drug effects were measured by means of saccadic and smooth pursuit eye movements and visual analog lines obtained from the scales of Bond and Lader. There were no pharmacokinetic differences between the Japanese and white subjects. Clearance of nitrazepam was 0.91 ± 0.165 mL/min/kg and 1.17 ± 0.492 mL/min/kg, and half‐life (t1/2) was 22.1 ± 4.96 hours and 21.5 ± 7.51 hours for the Japanese and European groups, respectively. Pharmacokinetic parameters showed no significant correlation with age, height, or weight. The average time‐effect curves for the different parameters were comparable between groups. Compared with placebo, both groups showed similar significant reductions in average peak velocity and increases in saccadic inaccuracy and reaction time. Visual analog scores showed clear sedation in the white subjects, but insignificant effects in the Japanese subjects. Smooth pursuit did not change significantly in either group. Slope and intercept of the concentration‐effect relationships for saccadic peak velocity showed considerable intersubject variability, but no clear differences between groups. The pharmacokinetics and pharmacodynamics of nitrazepam were similar in matched healthy Japanese and white subjects. Interethnic comparative studies are feasible, and provide meaningful information about potential racial differences in disposition and action of drugs. Such studies can form a rational basis for comparative clinical trials.

Published
1998
Full Text
View/download PDF

14. CNS effects of sumatriptan and rizatriptan in healthy female volunteers.

Author

van der Post J, Schram MT, Schoemaker RC, Pieters MS, Fuseau E, Pereira A, Baggen S, Cohen AF, and van Gerven JM

Subjects
Adult, Affect drug effects, Cognition drug effects, Cross-Over Studies, Dizziness chemically induced, Double-Blind Method, Electroencephalography drug effects, Eye Movements drug effects, Female, Headache chemically induced, Humans, Hypnotics and Sedatives pharmacology, Nerve Tissue Proteins administration & dosage, Nerve Tissue Proteins physiology, Neuropsychological Tests, Postural Balance drug effects, Reaction Time drug effects, Receptor, Serotonin, 5-HT1B, Receptor, Serotonin, 5-HT1D, Receptors, Serotonin drug effects, Receptors, Serotonin physiology, Recognition, Psychology drug effects, Reference Values, Serotonin Receptor Agonists adverse effects, Serotonin Receptor Agonists pharmacokinetics, Sumatriptan adverse effects, Sumatriptan pharmacokinetics, Temazepam adverse effects, Temazepam pharmacokinetics, Temazepam pharmacology, Triazoles adverse effects, Triazoles pharmacokinetics, Tryptamines, Brain drug effects, Serotonin Receptor Agonists pharmacology, Sumatriptan pharmacology, Triazoles pharmacology
Abstract

This study investigates the CNS effects of sumatriptan and rizatriptan, with temazepam as an active comparator, in healthy female volunteers. Sixteen volunteers completed a randomized, double-blind, crossover study and on four separate occasions received either 100 mg sumatriptan, 20 mg rizatriptan or 20 mg temazepam. The main parameters were eye movements, EEG, body sway, visual analogue scales and a cognitive test battery. Rizatriptan and sumatriptan decreased saccadic peak velocity by 18.3 (95% CI: 5.7, 30.8) and 15.0 (2.2, 27.9) degrees/sec, respectively, about half the decrease induced by temazepam (35.0 (22.1, 47.8) degrees/sec). Body sway increased (30% for rizatriptan (16%, 45%) and 14% for sumatriptan (1%, 27%), respectively). Temazepam caused larger, similar effects. In contrast to temazepam, sumatriptan and rizatriptan decreased reaction times of recognition tasks and increased EEG alpha power (significant for sumatriptan, 0.477 (0.02, 0.935). Therapeutic doses of sumatriptan and rizatriptan caused CNS effects indicative of mild sedation. For EEG and recognition reaction times the effects were opposite to temazepam, indicating central stimulation.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results